Drug Profile
5E3623
Latest Information Update: 17 Nov 2006
Price :
$50
*
At a glance
- Originator Eisai Co Ltd
- Class Antihypertensives
- Mechanism of Action Type 1 cyclic nucleotide phosphodiesterase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Hypertension
Most Recent Events
- 25 Sep 1997 Preclinical development for Hypertension in Japan (Unknown route)